Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
- PMID: 31473652
- PMCID: PMC6923940
- DOI: 10.1136/bmjspcare-2019-001770
Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care
Abstract
Objectives: Despite recent advances in thoracic oncology, most patients with metastatic lung cancer die within months of diagnosis. Aggressiveness of their end-of-life (EOL) care has been the subject of numerous studies. This study was undertaken to evaluate the literature on aggressive inpatient EOL care for lung cancer and analyse the evolution of its aggressiveness over time.
Methods: A systematic international literature search restricted to English-language publications used terms associated with aggressiveness of care, EOL and their synonyms. Two independent researchers screened for eligibility and extracted all data and another a random 10% sample of the abstracts. Electronic Medline and Embase databases were searched (2000-20 September 2018). EOL-care aggressiveness was defined as follows: 1) chemotherapy administered during the last 14 days of life (DOL) or new chemotherapy regimen during the last 30 DOL; 2) >2 emergency department visits; 3) >1 hospitalisation during the last 30 DOL; 4) ICU admission during the last 30 DOL and 5) palliative care started <3 days before death.
Results: Among the 150 articles identified, 42 were retained for review: 1 clinical trial, 3 observational cohorts, 21 retrospective analyses and 17 administrative data-based studies. The percentage of patients subjected to aggressive therapy seems to have increased over time. Early management by palliative care teams seems to limit aggressive care.
Conclusions: Our analysis indicated very frequent aggressive EOL care for patients with lung cancer, regardless of the definition used. The extent of that aggressiveness and its impact on healthcare costs warrant further studies.
Keywords: aggressive care; end-of-life care; healthcare costs; lung cancer.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Figures
Similar articles
-
Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care.Clin Lung Cancer. 2021 May;22(3):e320-e328. doi: 10.1016/j.cllc.2020.05.017. Epub 2020 May 23. Clin Lung Cancer. 2021. PMID: 32646653
-
Palliative Chemotherapy Affects Aggressiveness of End-of-Life Care.Oncologist. 2016 Jun;21(6):771-7. doi: 10.1634/theoncologist.2015-0445. Epub 2016 Apr 18. Oncologist. 2016. PMID: 27091417 Free PMC article.
-
Latent class analysis identifies three subtypes of aggressive end-of-life care: a population-based study in Taiwan.Eur J Cancer. 2013 Oct;49(15):3284-91. doi: 10.1016/j.ejca.2013.05.005. Epub 2013 Jun 4. Eur J Cancer. 2013. PMID: 23756054
-
End-of-life communication in the intensive care unit.Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):433-42. doi: 10.1016/j.genhosppsych.2010.04.007. Epub 2010 May 26. Gen Hosp Psychiatry. 2010. PMID: 20633749 Review.
-
Integrating early palliative care (EPC) in the management of lung cancer: The role of the thoracic oncologist.Lung Cancer. 2015 Nov;90(2):135-8. doi: 10.1016/j.lungcan.2015.08.016. Epub 2015 Sep 2. Lung Cancer. 2015. PMID: 26341958 Review.
Cited by
-
Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.J Clin Oncol. 2024 May 10;42(14):1646-1654. doi: 10.1200/JCO.23.01045. Epub 2024 Mar 13. J Clin Oncol. 2024. PMID: 38478794 Free PMC article.
-
Dual balanced augmented topological noncoding RNA disease triplet association in heterogeneous graphs.Brief Bioinform. 2025 Jul 2;26(4):bbaf389. doi: 10.1093/bib/bbaf389. Brief Bioinform. 2025. PMID: 40753538 Free PMC article.
-
Initial Experience after Transition to Immune Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer Treated in a Rural Healthcare Region.Cureus. 2020 Feb 18;12(2):e7030. doi: 10.7759/cureus.7030. Cureus. 2020. PMID: 32211263 Free PMC article.
-
End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting.J Clin Oncol. 2023 Oct 20;41(30):4729-4738. doi: 10.1200/JCO.22.02180. Epub 2023 Jun 20. J Clin Oncol. 2023. PMID: 37339389 Free PMC article.
-
Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis.EClinicalMedicine. 2024 Mar 21;71:102561. doi: 10.1016/j.eclinm.2024.102561. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38549585 Free PMC article.
References
-
- World Health organization. International agency for research on cancer. press release No. 223, latest world cancer statistics, 2013. Available: http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf
-
- National Cancer Institute,, SEER Program . Seer STAT fact sheet: lung and bronchus cancer, 2014. Available: http://seer.cancer.gov/statfacts/html/
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical